Press Releases



Mediclinic Intnl plc - Director/PDMR Shareholding

30/05/2018
RNS Number : 7232P
Mediclinic International plc
30 May 2018
 

Mediclinic International plc
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC

JSE Share Code: MEI
NSX Share Code: MEP

ISIN: GB00B8HX8Z88

LEI: 2138002S5BSBIZTD5I60

("Mediclinic", the "Company" or the "Group")

 

30 May 2018

 

NOTIFICATION OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

 

On 24 and 25 May 2018, Mr Danie Meintjes, Chief Executive Officer of Mediclinic International plc, sold a total of 49 423 shares in the Company, being the shares awarded to Mr Meintjes in 2014 under the Mediclinic International Limited Forfeitable Share Plan, which vested on 31 May 2017. Mr Meintjes retained the totality of the shares at the time but has now disposed of them to cover personal tax liabilities. Mr Meintjes continues to hold 123 900 shares in the Company.

 

The notification below is made in accordance with Articles 19.1 and 19.3 of the Market Abuse Regulation.

 

1.

Details of PDMR / person closely associated with them ("PCA")

 

a)

Name

Mr Daniël Petrus Meintjes

 

2.

Reason for the notification

 

a)

Position / status

Chief Executive Officer of the Company

 

b)

Initial notification / amendment

Initial Notification

 

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

Name

Mediclinic International plc

 

b)

LEI

2138002S5BSBIZTD5I60

 

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

Description of the financial instrument

 

Identification Code

Ordinary Shares

 

 

GB00B8HX8Z88

 

b)

Nature of the transaction

Sale of shares awarded in 2014 under the Mediclinic International Limited Forfeitable Share Plan, which vested on 31 May 2017

 

 

c)

Price(s) and volume(s)

Price(s)

Volume(s)

ZAR 110.01 per share

17 423

 

d)

Aggregated information

 

Aggregated volume

 

Price

 

 

 

17 423

 

ZAR 110.01

 

 

e)

Date of the transaction

24 May 2018

 

 

f)

Place of the transaction

Johannesburg Stock Exchange

 

 

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

Description of the financial instrument

 

Identification Code

Ordinary Shares

 

 

GB00B8HX8Z88

 

b)

Nature of the transaction

Sale of shares awarded in 2014 under the Mediclinic International Limited Forfeitable Share Plan, which vested on 31 May 2017

 

c)

Price(s) and volume(s)

Price(s)

Volume(s)

ZAR 107.01 per share

32 000

 

d)

Aggregated information

 

Aggregated volume

 

Price

 

 

 

32 000

 

ZAR 107.01

 

 

e)

Date of the transaction

25 May 2018

 

 

f)

Place of the transaction

Johannesburg Stock Exchange

 

 

 

 

About Mediclinic International plc

 

Mediclinic is an international private healthcare services group with operating divisions in Switzerland, Southern Africa (South Africa and Namibia) and the United Arab Emirates. Its core purpose is to enhance the quality of life of patients by providing acute care, specialist-orientated, multi-disciplinary healthcare services. Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, an LSE-listed and UK-based private healthcare group.

 

Mediclinic comprises 75 hospitals and 28 clinics. Hirslanden operates 17 private acute care facilities and 4 clinics in Switzerland with more than 1 800 inpatient beds; Mediclinic Southern Africa operates 49 hospitals and 2 day clinics throughout South Africa and 3 hospitals in Namibia with more than 8 100 inpatient beds in total; and Mediclinic Middle East operates 6 hospitals and 22 clinics with more than 700 inpatient beds in the United Arab Emirates.

 

Mediclinic has a primary listing on the Main Market of the LSE in the United Kingdom, with secondary listings on the JSE in South Africa and the NSX in Namibia.

 

For further information, please contact:

  Company Secretary, Link Company Matters Limited

Jayne Meacham / Caroline Emmet

+44 (0)20 7954 9569

 

Investor Relations, Mediclinic International plc

James Arnold, Head of Investor Relations

ir@mediclinic.com

+44 (0)20 3786 8181

 

Media queries

FTI Consulting

Brett Pollard/Debbie Scott - UK

+44 (0)20 3727 1000

Sherryn Schooling - South Africa

+27 (0)21 487 9000

 

Registered address: 6th Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom

Website: www.mediclinic.com

Joint corporate brokers: Morgan Stanley & Co International plc and UBS Investment Bank

JSE sponsor: Rand Merchant Bank (A division of FirstRand Bank Limited)

NSX sponsor: Simonis Storm Securities (Pty) Ltd


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHBXGDUSSXBGIG